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Somatosensorypredictorsof response topregabalin in
painful chemotherapy-induced peripheral neuropathy:
a randomized, placebo-controlled, crossover study
Alexander Hinckera,b, Karen Freya, Lesley Raoa,b, Nina Wagner-Johnstonc, Arbi Ben Abdallaha, Benjamin Tand,
Manik Amind, Tanya Wildesa,d, Rajiv Shaha,b, Pall Karlssone,f, Kristopher Bakosg, Katarzyna Kosickah,
Leonid Kagani, Simon Haroutouniana,b*
Abstract
Painful chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and treatment-resistant sequela of many chemotherapeutic
medications. Ligands of a2d subunits of voltage-gated Ca21 channels, such as pregabalin, have shown efficacy in reducing mechanical
sensitivity in animal models of neuropathic pain. In addition, some data suggest that pregabalin may be more efficacious in relieving
neuropathic pain in subjects with increased sensitivity to pinprick. We hypothesized that greater mechanical sensitivity, as quantified by
decreasedmechanical pain threshold at the feet, would be predictive of a greater reduction in average daily pain in response to pregabalin vs
placebo. In a prospective, randomized, double-blinded study, 26 patients with painful CIPN from oxaliplatin, docetaxel, or paclitaxel received
28-day treatment with pregabalin (titrated to maximum dose 600 mg per day) and placebo in crossover design. Twenty-three participants
were eligible for efficacy analysis.Mechanical pain thresholdwas not significantly correlatedwith reduction in average pain (P5 0.97) orworst
pain (P5 0.60) in response to pregabalin. Therewas no significant difference between pregabalin and placebo in reducing average daily pain
(22.5% vs 10.7%, P5 0.23) or worst pain (29.2% vs 16.0%, P5 0.13) from baseline. Post hoc analysis of patients with CIPN caused by
oxaliplatin (n518) demonstrated a larger reduction inworst painwith pregabalin thanwith placebo (35.4%vs14.6%,P50.04). In summary,
baseline mechanical pain threshold tested on dorsal feet did not meaningfully predict the analgesic response to pregabalin in painful CIPN.
Keywords:Chemotherapy-induced peripheral neuropathy, Pregabalin, Quantitative sensory testing, Mechanical pain threshold,
Oxaliplatin, Paclitaxel, Docetaxel
1. Introduction
Chemotherapy-induced peripheral neuropathy (CIPN) affects
25% to 90% of patients treated with anticancer treatments such
as platinum compounds, taxanes, and vinca alkaloids.
Chemotherapy-induced peripheral neuropathy is frequently
a dose-limiting side effect of these medications, which can
increase the rate of treatment failure.12,39 In addition, chronic
CIPN, which affects anywhere from 10% to 50% of patients
treated with these drugs,4,33,40 reduces quality of life even in
patients whose cancers are in remission.22
Evidence of successful treatment of painful CIPN is very limited;
only one large, positive, randomized controlled study on the
treatment of CIPN has been published. This study demonstrated
marginal effectiveness of duloxetine, a serotonin–norepinephrine
reuptake inhibitor.38 Venlafaxine, another serotonin-
norepinephrine reuptake inhibitor, has shown efficacy in the
possible secondary prevention of oxaliplatin-induced neuropathy
after the onset of acute neuropathy symptoms.11 Numerous
medications have failed to show efficacy compared with
placebo,5,25,36 although most studies have used composite
neuropathy scores or symptom scores, rather than pain intensity,
as primary outcomes.
The mechanisms of injury in CIPN, and the transition from
acute to chronic neurotoxicity, are not fully understood, although
many chemotherapy agents share pathological findings in CIPN,
eg, common final pathway of axonal mitochondrial damage.29,35
In rats, CIPN caused by oxaliplatin and taxanes (paclitaxel and
docetaxel) results in overexpression of a2d subunits of voltage-
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gatedCa21 channels in the dorsal root ganglion16 and spinal cord
dorsal horn.41 This suggests that modulating neuronal Ca21
channel function by a2d ligands may be effective in treating
CIPN. Administration of a2d ligands gabapentin27,28,41 and
pregabalin2,34 reduced mechanical and thermal hypersensitivity
in rat models of CIPN caused by oxaliplatin and taxanes.
Neuronal voltage-gated Ca21 channels as targets for treating
CIPN remain largely unexplored clinically. The only published
randomized clinical trial of gabapentin in CIPN was negative,36
although it did not have pain as an inclusion criterion;
observational data suggest clinical effectiveness of pregabalin
in oxaliplatin- and taxane-induced peripheral neuropathy.32
In neuropathic pain, the “one size fits all” pharmacotherapy
approach yields unsatisfactory effect sizes.14 A few studies have
prospectively demonstrated that sensory phenotyping based on
quantitative sensory testing (QST) predicts response to treat-
ment. For example, Demant et al.9 demonstrated that the irritable
nociceptor phenotype predicts response to oxcarbazepine.
However, most such data come from post hoc analyses of
clinical trials7,37 or from uncontrolled trials.42 For example, post
hoc analysis showed that treatment of neuropathic pain with
botulinum toxin A was more efficacious in patients with
allodynia identified by QST.3 Similarly, in an HIV sensory
neuropathy study that was negative overall, patients with
hyperalgesia to pinprick reported a significant analgesic
response to pregabalin.37 The application of such phenotyping
to CIPN remains unexplored.
Based on findings that pinprick hypersensitivity may predict
responsiveness to pregabalin, together with animal data and
observational clinical data supporting the usefulness of pregabalin in
CIPN, we hypothesized that mechanical hypersensitivity to pinprick
(lower mechanical pain threshold [MPT]) may predict better analgesic
response to pregabalin treatment in patients with painful CIPN.
The objective of this prospective, randomized, double-blind,
placebo-controlled crossover trial was to determine whether
baseline MPT predicts the response to pregabalin in patients with
painful CIPN.
2. Methods
This investigator-initiated study was approved by theWashington
University Institutional Review Board (#201501067). Written
informed consent was obtained from all participants, and the
study was registered at ClinicalTrials.gov (NCT02394951).




Participantswere eligible for this study if theymet the followingcriteria:
(1) age .18 years; (2) distal, symmetric pain in both feet that
appeared within 12 weeks of treatment with paclitaxel, docetaxel, or
oxaliplatin (or any combination of these); (3) pain persistence for at
least 2months; (4) scores$4 on the Douleur Neuropathique 4 (DN4)
questionnaire6; (5) pain of average daily intensity .3 on 0 to 10
numerical rating scale (NRS) in the past week; and, (6) if of
childbearing potential, agreed to use contraception for the duration
of the study. Exclusion criteria were hypersensitivity to or current
treatment with pregabalin, CIPN that may be associated with
previous treatment with a vinca alkaloid, current treatment with
a vinca alkaloid, any prechemotherapy signs of distal symmetric
polyneuropathy, creatinine clearance ,30 mL/minute, ALT or AST
.3 times the normal limit, planned surgeries or radiation treatment
within 10 weeks after study inclusion, inability to complete pain self-
report, current or planned pregnancy or lactation, seizure disorder
treated with anticonvulsants, or current participation in a trial with
another investigational agent. Vinca alkaloids were specifically
excluded because some evidence suggests these chemotherapeu-
tics may not lead to Ca21channels a2d subunit upregulation in the
dorsal horn or dorsal root ganglia inCIPN in themanner thanplatinum
or taxane medications do.16 Participants receiving gabapentin,
anticonvulsants, or NSAIDs for pain were required to discontinue
thesemedications before study initiation. Participants could continue
tricyclic antidepressants and serotonin and norepinephrine reuptake
inhibitors. Participants could continue standing dose of opioids at
a maximum dose of 60mg oral morphine equivalent per day, but as-
needed doses of opioids were not allowed for treatment of CIPN.
However, as-needed short-acting opioids (with or without acetamin-
ophen) for pain other than CIPN were allowed up to 4 daily doses,
with daily recording of analgesic consumption.
2.2. Acquisition of baseline characteristics
The sequence of events for each participant enrolled in the
study is shown in Supplementary Figure 1 (available at http://
links.lww.com/PAIN/A782). All participants attended an initial
screening visit. At this visit, participants underwent sensory
mapping of their lower extremities to sensory perception of static
mechanical stimulation (#6.10 Semmes-Weinstein monofila-
ment; North Coast Medical, Gilroy, CA), dynamic mechanical
stimulation (SENSELab Brush-05; Somedic, Norra Mellby,
Sweden), and 40˚C warmth and 20˚C cold (Rolltemp II; Somedic).
These stimuli are not routinely painful to healthy people, or when
applied to unaffected areas of skin in patients with neuropathy.
For each sensory modality, participants were asked whether they
felt that their sensation of the stimulus was decreased or
increased compared with the sensation on unaffected skin and
whether the sensation was painful. Participants were designated as
having hypoesthesia, hyperesthesia, or allodynia if they had
decreased sensation, increased sensation, or pain (respectively) at
the site of their spontaneous neuropathic pain (dorsal feet).
Hyperesthesia and allodynia could be present at the same site.
Participants also completed the following questionnaires: Brief Pain
Inventory (BPI) (from which baseline average and worst daily pain
values were drawn, using a 0-10 NRS); Neuropathic Pain Symptom
Inventory (NPSI); Depression, Anxiety, and Positive Outlook Scale
(DAPOS); and the 9-item Sleep Problems Index (SPI II). Participants
were trained in the use of tablet computers on which they
documented daily pain scores, study drug use, and side effects.
All participants underwent a QST battery per details below.
2.3. Quantitative sensory testing protocol
Quantitative sensory testing was performed at the first and third
study visits at Washington University Clinical Trials Research Unit
(CTRU). Testing was performed on the dorsal midfoot of themore
painful foot. If feet were equally painful, onewas chosen randomly
for testing. The ipsilateral shoulder served as a control area.
Shoulder was chosen as control site (in lieu of typically used volar
forearm), as we suspected some subjects to have sensory
changes in distal upper extremities.40
Quantitative sensory testing was performed following a pre-
viously published method.21 We tested, using the method of
limits: mechanical detection threshold using Semmes-Weinstein
monofilaments (North Coast Medical), MPT and wind-up ratio
using weightedmetal PinPrick stimulators (MRCSystemsGmbH,
Heidelberg, Germany), cold detection threshold, warmth
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detection threshold, cold pain threshold, heat pain threshold
(HPT) (using Thermal Sensory Analyzer; TSA-II, Medoc, Ramat
Yishai, Israel), and vibration detection threshold using a 64-Hz
tuning fork. For a given parameter, the extent of hyposensitivity/
hypersensitivity was measured by the value of the parameter at
the affected site minus the value at the control site.
We measured conditioned pain modulation (CPM) using the
method of levels via the Q-Sense Thermal Analyzer (Medoc). This
machine is equipped with 2 Peltier thermodes whose tempera-
ture could be programmed independently. The testing stimulus
was determined by temperature that elicits heat pain of 60 on
a 0 to 100 NRS (Pain-60). At the time of protocol writing, the
conditioning stimulus was planned as a hot stimulus set to
a temperature that elicits a pain of 30 on a 0 to 100 NRS. After
pilot testing before study initiation, the protocol was modified to
deliver a cold conditioning stimulus of 16˚C because it provided
more consistent CPM response (unpublished data).
At first, the test stimulus was applied at the nondominant
forearm twice, 30 seconds apart, and the average pain value on
0 to 100 NRS was obtained. After a 10-minute break, the
conditioning stimulus was applied to the dominant forearm for 60
seconds; during the last 30 seconds of conditioning, 2 Pain-60
heat stimuli were applied to the nondominant forearm. The
procedure was repeated twice. Conditioned painmodulationwas
measured as the difference between NRS of Pain-60 stimuli with
and without the contralateral cold conditioning (average score of
2 tests). Conditioned pain modulation was measured at the
participants’ forearms only and not at the affected sites.
All sensory assessments were performed by the same trained
research coordinator, who remained blinded to treatment
sequence allocation throughout the study.
2.4. Study medication administration periods
Patients were randomized to receive pregabalin, followed by
placebo, or vice versa with a 1:1 allocation ratio. The study
pharmacist used an electronic random number generator to
randomize participants in blocks of 8 without stratification. All
study team members were blinded to the treatment allocation
except the study pharmacist, who did not participate in patient
enrollment or any data collection. Pregabalin (or identical looking
placebo capsules, provided by Pfizer Inc) was administered for 4
weeks in each study period. The dose was increased as follows:
75 mg twice a day (BID) for 3 days, 150 mg BID for 3 days, then
300 mg BID until and including day 28.
In the event of any grade 2 adverse events (Common
Terminology Criteria for Adverse Events—CTCAE version 4.0),
the dosewas reduced to the last dose before dose increase. If the
adverse effect diminished to #grade 1, one attempt to dose
escalate was allowed after 3 additional days. If the dose
escalation was not tolerated (ie, recurrent grade 2 adverse event),
the treatment was continued at the previous (lower) dose until day
28. Any CTCAE $grade 3 triggered participant withdrawal from
the study. During the first treatment sequence, the participants
were asked to guess whether they were receiving placebo or
pregabalin.
At the end of treatment sequence, the dosewas tapered over 3
days (eg, 150 mg BID for 2 days, then 75 mg BID for 1 additional
day) followed by 10 days of study treatment-free washout (end of
week 6). In participants with creatinine clearance 30 to 60
mL/minute, the target (maximum) dose was 300mg/day. In these
participants, the dose was tapered over 3 days of 75 mg BID
dosing. If participant’s highest tolerable maintenance dose was
75mgBID, the taper schedulewas 75mgonce a day over 3 days.
Acetaminophen (paracetamol) 500 mg tablets were provided
as rescue medication, as the only allowed analgesic to use for
breakthrough pain, in doses up to 4000 mg/day.
We used an electronic diary system on a tablet device provided
to each participant for daily assessment of pain ratings,
adherence to medications, and side-effect reporting. On each
day beginning with the first day of study medication administra-
tion, participants recorded via the tablet device the amount (in
pills) of study medication used, their average/worst pain severity,
any adverse effects, and whether they believed such effects were
due to the study medication. Medication consumption was not
directly observed by members of the study team, but pill count
(both for study drug and acetaminophen) was performed at the
end of each treatment sequence. The data entered to the tablet
device were stored on an encrypted and password-protected
cloud server; these data were accessible in real time to study
team members for adverse effect monitoring.
The participants were scheduled to return on day 286 2 days
for visit 2 to complete the questionnaires. After the washout
period (end of week 6), the participants returned for visit 3, before
the second treatment sequence. The participants underwent
QST and CPM procedures and completed appropriate ques-
tionnaires (BPI, NPSI, DAPOS, and SPI II). Thereafter, the second
4-week treatment sequence was scheduled for weeks 7 to 10,
according to the same titration schedule as sequence 1. Three-
day dose tapering was practiced at the end of the second
treatment sequence in the same manner as was performed for
the first treatment. The participants returned for the final
assessment visit (visit 4) approximately 3 days after end of week
10. Safety and efficacy data, blood draw for determining plasma
pregabalin concentration, and an optional skin biopsy in
participants who agreed were obtained at visit 4. Pregabalin
presence in plasma was determined to confirm adherence to
treatment and correct pregabalin vs placebo allocation.
2.5. Pregabalin concentration assay
The analytical method for determining the concentration of
pregabalin in plasma was adapted from Martinc et al.30
Specifically, Agilent 1260 HPLC system equipped with fluores-
cent detector was used. Separation was achieved with Agilent
InfinityLab Poroshell 120 EC-C18 column (100 3 4.6 mm,
2.7 mm) and a gradient flow of methanol: acetonitrile: ammonium
acetate buffer pH 5.0. Gabapentin was used as an internal
standard. Pregabalin retention timewas 11.2minutes, and limit of
quantification (LOQ) was 100 ng/mL.
2.6. Skin biopsy
In patients who provided consent, a 3-mm skin punch biopsy in
the lower leg (10 cmabove the lateral malleolus) was performed at
the final study visit. The biopsy specimen was placed in
Zamboni’s fixative overnight, then transferred to a glycerol-
based cryoprotection fluid, and subsequently frozen and stored
at 280˚C. Frozen tissues were cut into 50-mm sections before
immunostaining with PGP 9.5 antibody for the determination of
intraepidermal nerve fiber density (IENFD) per published guide-
lines.23,26 A researcher blinded to patient allocation/results
analyzed the skin biopsies.
2.7. Statistical methods
The primary outcome of the study was the comparison of the
slopes of 2 correlations: baseline MPT vs percent pain reduction
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with pregabalin and baseline MPT vs percent pain reduction with
placebo.
Pain reduction (both for average and worst pain) was
determined using the difference in pain intensity from baseline
to the average of daily pain on days 24 to 28 (ie, last 5 days) of
each treatment phase, obtained from the patient diaries. For
patients whose data for the last week was missing, we used the
last observation carried forward method of imputation.
The sample size calculation was performed for detecting
a significant difference between correlations on percent pain
reduction vs MPT slopes of pregabalin and placebo in linear
bivariate regression. To detect 0.3 (SD 5 0.5) difference in
correlation coefficients between the 2 slopes, with 85% power
and a 5 0.05, 27 participants were required in this crossover
design. We aimed to recruit 35 patients to account for possible
20% dropout rate.
As secondary analyses, we compared pain reduction with
pregabalin (day 0-28) vs placebo for both average and worst daily
pain, using paired t-tests. In addition, we performed the Fisher
exact test to compare the proportion of patients with $30% and
$50% reduction in average and worst pain intensity from
baseline with pregabalin vs placebo. Number needed to treat
(NNT) was calculated from this proportion of responders to
pregabalin and placebo.13 We compared the rates of adverse
events and the proportions of participants experiencing any
adverse event using the Fisher exact test.
In prespecified exploratory analyses, we examined the
associations between other QST variables (mechanical detection
threshold, warmth detection threshold, cold detection threshold,
heat pain threshold, cold pain threshold, vibration detection
threshold, wind-up ratio, and conditioned pain modulation) and
response to pregabalin and placebo. In addition, we examined
the association between hyperesthesia or allodynia to cold,
warmth, static mechanical stimulation, and dynamic mechanical
stimulation, and the response to pregabalin and placebo.We also
examined the value of clinically significant scores in each NPSI
domain (defined as a score $3) in predicting response to
pregabalin vs placebo. Because the majority of patients’ CIPN
was associated with oxaliplatin treatment, we performed a post
hoc subgroup analysis examining the efficacy outcomes in
patients with only oxaliplatin-induced peripheral neuropathy.
3. Results
Study recruitment began in April 2015. Due to slower-than-
anticipated recruitment, the study sponsor requested the study to
be terminated in March 2018, before meeting the recruitment
goal. Overall, 26 patients were enrolled in the study (Fig. 1). Five
participants (19%) voluntarily withdrew during the pregabalin
treatment phase, reporting hypoglycemia (n5 1), urticaria (n5 1),
stomach pain and constipation (n 5 1), dizziness, blurred vision,
somnolence, and urticaria (n5 1), and small bowel obstruction (n
5 1). One participant (4%) voluntarily withdrew during the placebo
treatment phase, reporting uncontrolled pain after discontinuing
prestudy analgesics. Of these, 2 participants (8%) did not begin
the second arm of the study (pregabalin for one, placebo for the
other); these patients were censored from any outcomes
examining changes in pain. One participant (4%) initiated both
arms but refused the visit 3 QST; this participant was included in
analysis of changes in pain but not in analysis of QST as
a predictor of response to treatment.
Table 1 shows participant demographics (Supplementary
Table 1 shows baseline QST parameters; available at http://
links.lww.com/PAIN/A782). Notably, most patients (88%) initially
developed neuropathy symptoms while actively receiving chemo-
therapy, and oxaliplatin was the causative chemotherapeutic in
81% of cases. Average and worst daily pain severity in our cohort
before therapy were 5.3 and 5.6 on a 0 to 10 NRS, respectively.
Figure 2 and Table 2 show changes in average and worst pain
over time. There were no significant differences in baseline
average pain (4.46 2.1 vs 4.36 SD 1.9, P5 0.41) or worst pain
(5.1 6 2.2 vs 5.3 6 2.3, P 5 0.41) before initiating pregabalin or
placebo treatment. Overall, the absolute reduction in average
daily pain on 0 to 10 NRS was 0.86 1.1 with pregabalin, and 0.5
6 1.1 with placebo (P 5 0.08); this represented a 22.5% and
10.7% reduction in average daily pain, respectively (P 5 0.23).
There was no association between tolerable daily dose and
percent reduction in average daily pain (R2, 0.001) or worst daily
pain (R25 0.002). Numbers of patients needed to treat (NNT) with
pregabalin for achieving$30% and$50% reductions in average
pain were 6.2 and 12.5, respectively. The absolute reduction in
worst daily pain on 0 to 10NRSwas 1.46 1.3with pregabalin use
and 0.96 1.7 with placebo (P5 0.25); this represented a 29.2%
and 14.0% reduction in worst daily pain, respectively (P 5 0.13).
The NNT for achieving$30% and$50% reductions in worst pain
with pregabalin were 4.2 and 8.3, respectively. Average daily
acetaminophen intake was not significantly different between
pregabalin vs placebo treatment phases; 213 mg 6 364 mg vs
374 mg 6 712 mg, respectively (P 5 0.19).
Figure 3 shows the correlation between MPT and percent
reduction in average (Fig. 3A) and worst (Fig. 3B) daily pain with
pregabalin (blue) and placebo (red). There was no significant
association between MPT and reduction in average pain (R2 5
0.08, P 5 0.20) and worst pain (R2 5 0.08, P 5 0.19) with
pregabalin. These associations were not significantly different
from those seen between MPT and reduction in average pain (R2
5 0.05, P 5 0.31) and worst pain (R2 5 0.14, P 5 0.07) with
placebo. There was no significant difference in the slopes of MPT
vs pain reduction between the 2 arms for either average pain (P5
0.92) or worst pain (P5 0.60). The associations between baseline
MPT and changes in additional outcomes (BPI interference, BPI
severity, NPSI total, and SPI II scores) were also uniformly low
(ranging from R2 5 0.002 to R2 5 0.017) and nonsignificant. Of
the 8 other QST parameters examined, none of the correlations
between the QST parameter at baseline and the reduction in
average daily pain with pregabalin was significant.
The aforementioned primary outcome measures were based
on data collected on days 23 to 28 of treatment. Secondary
outcome measures (including NPSI, SPI II, BPI, and DAPOS)
were collected at a single time point occurring 1.5 6 1.7 days,
on average, after the last day of full dosing of the study drug;
participants received a tapered dose of the study drug for 3 days
after the last day of full dosing. Table 3 shows changes in NPSI,
SPI II, BPI, and DAPOS with pregabalin and placebo.
Neuropathic Pain Symptom Inventory subscales and the NPSI
total score decreased between 23% and 32% with pregabalin
vs 3% to 27% with placebo. The change in scores for pressing
pain (231.5% vs 126.3%, P 5 0.02), evoked pain (230.3% vs
112.2%, P 5 0.02), paresthesias/dysesthesias (228.3% vs 2
6.1%, P5 0.05), and total NPSI score (229.5% vs16.0%, P5
0.01) were more significant with pregabalin than with placebo.
Baseline MPT was not correlated with the changes in any of
these scales. As a post hoc analysis, we tested whether any
other QST parameters correlated with decrease in total NPSI
score; only HPT trended with a change in NPSI (P 5 0.049).
There were no significant differences between pregabalin and
placebo in changes on SPI II or any of the subscales of BPI or
DAPOS.
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After identifying that pregabalin induced significant decre-
ments in certain domains of the NPSI, we performed a post hoc
analysis testing whether the preintervention presence of clinically
meaningful intensity on any dimension of the NPSI (defined as
a score $3) was predictive of change in pain with pregabalin vs
placebo. There was no significant predictive value of any
dimension with regard to changes in average or worst pain (P
5 0.42-0.96; see Supplementary Table 2, available at http://
links.lww.com/PAIN/A782).
Post hoc subgroup analysis was performed examining partic-
ipants with oxaliplatin-induced CIPN (n5 19 starting both arms, n
5 18 completing QST). With regard to reduction in average daily
pain, the magnitude of pain reduction seen with pregabalin vs
placebo either in absolute change (1.056 1.2 vs 0.386 1.2 on 0-
10NRS,P5 0.12) or percent pain reduction (24.4%vs11.9%,P5
0.16) was not significant. Themagnitude of reduction in worst pain
was 1.72 6 1.2 vs 0.84 6 1.7 (P 5 0.14) for absolute pain
reduction, and 35.4% vs 14.6% (P 5 0.04) for percent pain
reduction in oxaliplatin-induced peripheral neuropathy. As with the
overall sample, correlations between MPT and percent pain
reduction were low (R2 5 0.08 for average pain; R2 5 0.13 for
worst pain) and were not significantly greater than the correlations
for placebo for average pain (P 5 0.56) or worst pain (P 5 0.60).
Proportions of participants experiencing adverse events with
each study medication are shown in Table 4. The majority of
participants experienced at least one adverse effect from both
pregabalin (92%) and placebo (84%), although the proportion of
patients experiencing any adverse effect did not differ between
the 2 arms (P 5 0.67, number needed to harm [NNH] 5 12.5).
Two types of adverse effects were experienced with a higher
frequency with pregabalin than with placebo: dizziness (17 [68%]
vs 4 [16%], P, 0.001, NNH5 1.9) and somnolence (22 [88%] vs
11 [44%], P 5 0.002, NNH 5 2.3). No adverse events were
experienced more frequently with placebo.
Twelve participants consented to punch biopsy of the distal
leg, all of whom completed both arms of the study and both QST
sessions. There was no significant correlation between IENFD
and percent reduction in average pain (R2 , 0.001) or worst pain
(R2 5 0.10) with pregabalin in these participants.
Results of static mechanical, dynamic mechanical, cold,
and warm stimulation to the distal leg are shown in Tables 5
and 6. In exploratory analyses, we examined whether
hyperesthesia or allodynia to these sensory modalities
predicted either greater reduction in average or worst daily
pain with pregabalin vs placebo (Table 5), or predicted
a greater likelihood to achieve a clinically meaningful improve-
ment of $30% in average or worst daily pain (Table 6). The
magnitude of difference between pregabalin and placebo for
reduction in average daily pain and worst daily pain was
greatest for participants with static mechanical allodynia
(33.5% 6 36.4% vs 6.1% 6 37.1% in average pain and
45.1%6 33.6% vs 7.3%6 36.9% in worst pain) as compared
to cold, warmth, or dynamic mechanical allodynia. However,
none of these tests had statistically significant predictive value
(P 5 0.12-0.95). In addition, although participants with
baseline cold hyperesthesia were more likely to show
a significant analgesic response to pregabalin (67% of
participants with hyperesthesia vs 23% participants without
hyperesthesia achieved$ 30% reduction in average pain, P5
0.05; not corrected for multiple comparisons), none of the
other evoked hyperesthesia/allodynia phenotypes were pre-
dictive of response to pregabalin or placebo.
When asked to guess which treatment they were receiving, 19
(73%) participants correctly identified their treatment allocation.
The result was significantly different from randomly guessing the
treatment allocation (P 5 0.02).
Plasma pregabalin concentrations were analyzed at the end
of the pregabalin arm for 20 participants and at the end of the
placebo arm for 23 participants. No participants had a detect-
able pregabalin level at the end of the placebo arm. Of
participants from whom pregabalin levels were collected at the
end of the pregabalin arm of the study, the mean pregabalin
dosing was 375 mg 6 165 mg/day. Mean time from last dose
to sample collection was 7.8 6 12.9 hours (5.0 6 4.1 hour
when excluding one outlier with time between last dose and
sample collection of 60 hours). Mean plasma concentration of
pregabalin was 4979 ng/mL 6 2779 ng/mL. Notably, 2 of 23
participants at the end of pregabalin treatment had plasma
Figure 1. Enrollment flowchart. Flow of participants through the study.
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Table 1
Participant demographic information divided by study medication administration order.
Pregabalin then placebo (n 5 12) Placebo then pregabalin (n 5 14) Total (n 5 26)
Age, y (SD) 65.1 (8.2) 59.9 (11.4) 62.3 (10.2)
Sex M/F (% male) 7/5 (58%) 11/3 (79%) 18/8 (69%)
Race:
White (%) 10 (83%) 14 (100%) 24 (92%)
Black (%) 2 (17%) 0 (0%) 2 (8%)
Primary cancer diagnosis prompting
chemotherapy:
Breast—2 (17%) Breast—N/A Breast—2 (8%)
Colorectal—8 (67%) Colorectal—8 (57%) Colorectal—16 (62%)
Pancreatic—1 (8%) Bile duct—1 (7%) Bile Duct—1 (4%)
Esophageal—1 (8%) Esophageal—3 (21%) Esophageal—4 (15%)
Gastric—1 (7%) Gastric—1 (4%)
Lung—1 (7%) Lung—1 (4%)
Pancreatic—1 (4%)
Causative agent, mean cumulative dose:
Docetaxel (%) 2 (17%), 647 mg N/A 2 (8%), 647 mg
Paclitaxel (%) N/A 3 (21%), 1203 mg 3 (12%), 1203 mg
Oxaliplatin (%) 10 (83%), 1484 mg 11 (79%), 1582 mg 21 (81%), 1535 mg
Onset of pain relative to chemotherapy:
During (%) 12 (100%) 11 (79%) 23 (88%)
0-6 weeks after discontinuation (%) N/A N/A N/A
6-12 weeks after discontinuation (%) N/A 3 (21%) 3 (12%)
Duration of pain:
, 6 mo (%) 3 (25%) 3 (21%) 6 (23%)
6-12 mo (%) 3 (25%) 6 (43%) 9 (35%)
12-24 mo (%) 2 (17%) 3 (21%) 5 (19%)
2-5 y (%) 3 (25%) 2 (14%) 5 (19%)
. 5 y (%) 1 (8%) 0 (0%) 1 (4%)
Baseline analgesic use (%) Duloxetine—1 (8%) Gabapentin—2 (14%) Duloxetine—1 (4%)
Venlafaxine—1 (8%) Hydrocodone/APAP—1 (7%) Gabapentin—2 (8%)
None—10 (75%) Oxycodone—1 (7%) Hydrocodone/APAP—1 (4%)
Tramadol—2 (14%) Tramadol—2 (8%)
None—8 (57%) Venlafaxine—1 (4%)
None—18 (69%)
Average pain over previous week, NRS 0-10 (SD) 5.6 (1.6) 5.1 (1.2) 5.3 (1.4)
Worst pain over previous 24 hours, NRS 0-10
(SD)
5.7 (2.2) 5.4 (1.9) 5.6 (2.0)
Neuropathic Pain Symptom Inventory (NPSI)
score:
Burning 3.4 (3.0) 2.6 (3.0) 3.0 (3.0)
Pressing 2.0 (1.9) 1.9 (2.6) 1.9 (2.6)
Paroxysmal 3.4 (3.0) 2.0 (2.1) 2.6 (2.6)
Evoked 3.3 (2.5) 3.2 (2.2) 3.3 (2.3)
Paresthesia/dysesthesia 5.2 (2.4) 5.5 (2.2) 5.3 (2.3)
Total 34.5 (22.5) 30.9 (17.2) 32.6 (19.5)
Brief Pain Inventory (BPI):
Pain severity 4.6 (1.8) 4.3 (1.3) 4.4 (1.5)
Pain interference 4.0 (2.6) 2.8 (2.5) 3.3 (2.5)
DAPOS
Depression 6.5 (2.0) 7.2 (3.5) 6.9 (2.9)
Anxiety 4.2 (2.1) 4.0 (1.2) 4.1 (1.6)
Positive outlook 12.8 (2.0) 12.1 (2.4) 12.4 (2.2)
SPI II 37.6 (17.8) 34.9 (25.1) 36.2 (21.6)
Any patients on gabapentin discontinued the medication before initiation of study protocols.
APAP, acetaminophen (paracetamol); BPI, Brief Pain Inventory; DAPOS, Depression, Anxiety, and Positive Outlook Scale; NPSI, Neuropathic Pain Symptom Inventory; NRS, Numerical Rating Scale; SPI II, 9-item Sleep Problems
Index II.
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pregabalin concentration below LOQ. Both of these partic-
ipants were receiving the lowest daily drug dose (75 mg) at the
end of dose taper off, and both had the longest intervals
between last pregabalin dose and collection of sample (60 and
13 hours).
4. Discussion
Chemotherapy-induced peripheral neuropathy is an iatrogenic
complication of several chemotherapeutic agents and is a neu-
ropathic pain condition where little evidence exists to support
efficacious treatments. Several studies have suggested that
somatosensory phenotyping in neuropathic pain can help
identifying subgroups of patients who are more likely to respond
to certain pharmacological interventions9,37,42 with the goal of
developing mechanism-based treatment approaches.20 Be-
cause animal models suggest that pregabalin is effective in
alleviating mechanical allodynia/hyperalgesia in neuropathic
pain,2,18,31 we hypothesized that patients with neuropathic pain
due to CIPN with greater mechanical sensitivity may be more
likely to respond to pregabalin.
Our results suggest that baseline MPT, a quantitative measure
of mechanosensitivity, is not a useful predictor of analgesic
response to pregabalin in patients with painful CIPN. It also did
not predict the degree of response to placebo. Both in our entire
cohort and in the subgroup of participants with oxaliplatin-
induced peripheral neuropathy, the associations between MPT
and reduction in average or worst daily pain with the study drug
were not significant. Similarly, when increased mechanosensi-
tivity was operationalized dichotomously based on allodynia to
static mechanical stimulation, there was no significant difference
in response to pregabalin vs placebo in participants with and
without allodynia. No other baseline QST parameter was found to
be a significant predictor of analgesic response to pregabalin in
this setting.
The overall reduction in average daily pain or worst daily pain
over 4 weeks of treatment with a target dose of 600 mg/day
pregabalin was not different from placebo. The NNTs for
achieving $50% reduction in average or worst daily pain with
pregabalin were 12.5 and 8.3 respectively, which is somewhat
larger than the recently reported NNTs of pregabalin in
neuropathic pain in general.14 Other outcome measures such
as BPI pain severity or interference, sleep, and DAPOS scores
were not different between the arms. However, several of the
neuropathic pain-specific measures on NPSI questionnaire
Figure 2. Changes in pain over time (by medication). (A) Changes in average
pain over time. (B) Changes in worst pain over time. Blue/circles—pregabalin,
red/squares—placebo. Points show mean daily pain, and lines represent the
bounds of the 95% confidence interval. NRS, Numerical Rating Scale.
Table 2
Effects of pregabalin and placebo on daily pain.
Trait Pregabalin (n 5 25) Placebo (n 5 25) Study statistic (P)
Baseline average pain (SD) 4.4 (2.1) 4.3 (1.9) 0.82
Baseline worst pain (SD) 5.1 (2.2) 5.3 (2.3) 0.41
Average pain, end of phase (average %
reduction)
3.5 (22.5%) 4.0 (10.7%) 0.23
Worst pain, end of phase (average % reduction) 3.7 (29.2%) 4.4 (14.0%) 0.13
Patients showing 30% reduction in average pain
(%)
10 (40.0%) 6 (24.0%) 0.364
Patients showing 50% reduction in average pain
(%)
5 (20.0%) 3 (8.0%) 0.474
Patients showing 30% reduction in worst pain
(%)
12 (48.0%) 6 (24.0%) 0.140
Patients showing 50% reduction in worst pain
(%)
7 (28.0%) 4 (16.0%) 0.496
Patients withdrawing from study due to side
effects while on medication (%)
5 (20.0%) 1 (4.0%) 0.189
Average daily acetaminophen use (mg) (SD) 213 (364) 374 (712) 0.190
Results are shown for participants who initiated both arms of the study. Paired t-tests were performed for per protocol analysis for baseline pain scores and changes in pain scores. The Fisher exact test was performed for
analysis of proportion of patients reaching pain reduction thresholds and proportion withdrawing from the study.
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(including evoked pain, paresthesia/dysesthesia, and total
NPSI score) showed larger improvement with pregabalin than
with placebo. Post hoc analysis suggested that the improve-
ment in worst pain was better with pregabalin than with
placebo in the subgroup of patients with oxaliplatin-induced
neuropathy, although this was not a prespecified outcome
measure.
There are multiple explanations for the lack of correlation
between MPT and response to pregabalin, which contrasts with
findings from rodent models. First, animal models of painful CIPN
may incompletely recapitulate the physiology of humans CIPN.
For example, rodent CIPN models consistently show mechanical
hypersensitivity of the paw.10,15,19 By contrast, only 5 of the 24
participants we tested (21%) reported static mechanical allody-
nia. This decreased mechanosensitivity is concordant with prior
research in humans with CIPN.40 In addition, voltage-gated Ca21
channels in the spinal cord dorsal horn are important mediators of
mechanical hypersensitivity in rodent models but may play
a lesser role in humans. Alternatively, a single QST modality such
as MPT may be an insufficiently sensitive test for assessing the
degree of a2d overexpression-associated neuronal hypersensi-
tivity. As a psychophysical test, MPT represents parameters
beyond the degree of neuronal hypersensitivity in the spinal cord
dorsal horn.17 Recent evidence suggests that tests involving less
subjective input from the patient better reflect the structural and
functional changes in peripheral neuropathic pain.24 Another
important consideration is that rodent pain models use mechan-
ical hypersensitivity as an outcome measure. The favorable
response to pregabalin in the evoked pain component of NPSI
suggests that outcome measures of evoked hypersensitivity
better reflect the tactile hypersensitivity in animal models.
Spontaneous pain, the key outcome measure in our study, does
not have parallel accurate representation in rodents; additional
research is required to align the phenotypic components of pain
vs outcome measures in animal to human translation. Further-
more, animal studies are beset by translational challenges such
as the intrinsic differences between species’ physiology, which
may affect both the response to neurotoxic chemotherapy
(single-agent in rodents vs combination multidrug protocols in
humans) and to therapeutic interventions, aswell as differences in
immune and psychological response to cancer and cancer
therapy.1 Finally, the human pain experience is a complex
interplay of signal transduction, transmission, perception, and
modulation; therefore, even if the calcium channel a2d subunit is
an appropriate therapeutic target, and MPT is an accurate assay
of its spinal overexpression or hyperactivity, our approach might
Table 3
Changes in pain and quality-of-life questionnaires after treatment.
Pregabalin (n 5 24) Placebo (n 5 24) P
Initial Final Change Initial Final Change
Neuropathic Pain Symptom Inventory (NPSI):
Burning 2.6 (2.8) 2.0 (2.8) 20.6 (223.8%) 2.9 (3.0) 2.8 (2.8) 20.1 (24.3%) 0.48
Pressing 2.3 (2.2) 1.5 (2.1) 20.7 (231.5%) 2.0 (2.5) 2.5 (2.7) 10.5 (126.3%) 0.02
Paroxysmal 3.0 (2.8) 2.1 (2.4) 20.9 (231.3%) 2.3 (2.2) 2.6 (2.5) 10.3 (110.7%) 0.07
Evoked 3.2 (2.2) 2.2 (1.7) 21.0 (230.3%) 2.7 (2.1) 3.1 (2.3) 10.3 (112.2%) 0.02
Paresthesia/dysesthesia 5.1 (2.3) 3.7 (2.6) 21.4 (228.3%) 5.1 (2.4) 4.8 (2.3) 20.3 (26.1%) 0.05
Total 33.0 (20.5) 23.3 (19.4) 29.8 (229.5%) 30.0 (18.9) 31.8 (20.9) 11.8 (16.0%) 0.01
Brief Pain Inventory (BPI):
Severity 4.2 (1.9) 3.4 (2.3) 20.8 (219.2%) 4.2 (1.8) 4.1 (2.3) 20.1 (22.7%) 0.09
Interference 3.1 (2.6) 2.5 (2.6) 20.6 (218.8%) 3.5 (2.6) 3.2 (2.7) 20.1 (24.3%) 0.38
Depression, Anxiety, and Positive Outlook Scale
(DAPOS):
Depression 6.6 (2.3) 6.4 (2.6) 20.2 (23.2%) 7.0 (3.0) 6.7 (3.2) 20.3 (24.7%) 0.66
Anxiety 4.1 (1.7) 4.0 (2.1) 20.1 (23.0%) 4.1 (2.1) 4.2 (2.2) 10.1 (12.0%) 0.54
Positive Outlook 12.1 (3.0) 12.4 (3.0) 20.3 (22.8%) 12.5 (2.3) 12.5 (2.5) 20.0 (20.0%) 0.49
Sleep Problem Index II (SPI II) 31.9 (20.4) 26.9 (19.0) 25.1 (215.9%) 34.7 (20.3) 30.6 (20.0) 24.1 (211.8%) 0.78
Values are only shown for participants who started both arms of the study (n5 24). Initial and final values are displayed as mean (SD). Changes are displayed as absolute change (percent change). Paired t-tests were performed
in all cases.
BPI, Brief Pain Inventory; DAPOS, Depression, Anxiety, and Positive Outlook Scale; NPSI, Changes in Neuropathic Pain Symptom Inventory; SPI II, Sleep Problem Index II after treatment with pregabalin and placebo.
Figure 3.Correlations betweenMPT and reduction in pain with pregabalin and
placebo. (A) Correlations betweenMPT and percent reduction in average pain.
(B) Correlations between MPT and percent reduction in worst pain. Blue/
circles—pregabalin, red/squares—placebo. MPT, mechanical pain threshold.
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have been too simplistic to capture the psychosocial factors that
contribute to the experience of human pain in the setting of CIPN.
Adverse effects were common for both pregabalin and
placebo. However, most were low grade. Of the adverse events
leading to withdrawals, 2 were possibly or likely unrelated to the
study treatment. One participant withdrew from the pregabalin
arm after a hypoglycemic episode, but this was in the setting of
introduction of an antihyperglycemic medication outside the
study. Another withdrew from the pregabalin arm because of
a small bowel obstruction in the setting of a new oncologic
diagnosis. Two of the remaining 23 participants found their
symptoms while taking pregabalin bothersome enough to
withdraw from the study, which exemplifies the need to identify
which patients are most likely to respond to which analgesics
because trialing multiple medications is not necessarily a benign
process.
This study has notable limitations. Most importantly, the study
was terminated early for slow recruitment. Overall, 23 participants
were included in the analysis of primary and secondary outcome
measures, when our initial goal was to enroll 27 participants. This
may have limited our power to detect significant changes, but the
primary outcome was overwhelmingly negative (P5 0.97), and it
is unlikely that it would have been affected by recruiting 4


















period (n 5 25)
Placebo—maintenance
period (n 5 25)
Placebo—taper




Dizziness 13 (52%) 17 (71%) 3 (14%) 17 (68%) 3 (12%) 2 (8%) 0 (0%) 4 (16%)****
Somnolence 18 (72%) 18 (75%) 10 (45%) 22 (88%) 9 (36%) 9 (36%) 5 (21%) 11 (44%)***
Dry mouth 10 (40%) 11 (46%) 6 (27%) 14 (56%) 7 (28%) 10 (40%) 5 (21%) 10 (40%)
Edema 4 (16%) 7 (29%) 4 (18%) 8 (32%) 7 (28%) 6 (24%) 4 (17%) 8 (32%)
Weight gain 2 (8%) 4 (17%) 0 (0%) 4 (16%) 1 (4%) 0 (0%) 0 (0%) 1 (4%)
Headache 9 (36%) 7 (29%) 3 (14%) 10 (40%) 9 (36%) 10 (40%) 7 (29%) 11 (44%)
Blurry vision 6 (24%) 7 (29%) 1 (5%) 8 (32%) 1 (4%) 4 (16%) 2 (8%) 4 (16%)
Nausea 2 (8%) 3 (13%) 4 (18%) 6 (24%) 5 (20%) 6 (24%) 3 (13%) 7 (28%)
Anxiety/
claustrophobia
0 (0%) 0 (0%) 1 (5%) 1 (4%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)




1 (4%) 0 (0%) 0 (0%) 1 (4%) 0 (0%) 1 (4%) 0 (0%) 1 (4%)
Small bowel
obstruction








0 (0%) 3 (13%) 0 (0%) 3 (12%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Urticaria 1 (4%) 1 (4%) 1 (5%) 2 (8%) 0 (0%) 1 (4%) 0 (0%) 1 (4%)
Epistaxis 1 (4%) 0 (0%) 0 (0%) 1 (4%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Urinary
incontinence
1 (4%) 1 (4%) 0 (0%) 1 (4%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Dyspnea 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (4%) 1 (4%) 1 (4%)
Hypertension 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (4%) 0 (0%) 0 (0%) 1 (4%)
Stiff joints/
pain in knees
0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (4%) 1 (4%) 1 (4%) 2 (8%)
Hypoglycemia 0 (0%) 1 (4%) 0 (0%) 1 (4%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Insomnia 0 (0%) 0 (0%) 1 (5%) 1 (4%) 0 (0%) 1 (4%) 0 (0%) 1 (4%)
Restlessness 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (4%) 1 (4%) 1 (4%) 1 (4%)
No AEs 2 (8%) 3 (13%) 6 (27%) 2 (8%) 6 (24%) 5 (20%) 9 (38%) 4 (16%)
Any AE 23 (92%) 21 (88%) 16 (73%) 23 (92%) 19 (76%) 20 (80%) 15 (63%) 21 (84%)
Adverse events experienced by study participants, by drug and phase of study. Titration period is days 1 to 7, maintenance period is days 8 to 28 (or until study drug terminated early), and taper period begins the day after
maintenance period ends. The Fisher exact test was performed for each adverse event comparing the proportion of participants who experienced the event at any point in the course of each study medication. *P , 0.05,
**P , 0.01, ***P , 0.005, ****P , 0.001.
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correlation between MPT and analgesic response. However, as
neither the primary outcome nor the secondary analysis, using
dichotomous operationalization of allodynia to static mechanical
stimulation, significantly predicted response to pregabalin, it is
unlikely that a strong relationship exists between increased
mechanosensitivity to pinprick in CIPN and preferential analgesic
response to pregabalin. On the other hand, the reduced number
of participants may have influenced the effect sizes of some of the
secondary outcomes, particularly considering that most partic-
ipants completed the posttreatment NPSI, BPI, DAPOS, and SPI
II questionnaires while tapering off the study drug.
Our study was not powered to allow for controlling for multiple
variables in the efficacy analysis. Furthermore, 6 participants had
painful CIPN lasting less than 6 months. Although reduction of
pain intensity with pregabalin and placebo was modest at best, it
is possible that some of these participants experienced
Table 5
Analgesic responses to pregabalin vs placebo for participants with and without allodynia to static mechanical, dynamic
mechanical, cold, and warm stimulation.
Group Percent reduction in average pain P Percent reduction in worst pain P
Pregabalin Placebo Difference Pregabalin Placebo Difference
Static mechanical allodynia?
Yes (n 5 5) 25.7 (30.7) 27.8 (24.1) 33.5 (36.4) 0.19 41.3 (19.6) 23.8 (30.0) 45.1 (33.6) 0.12
No (n 5 19) 21.7 (22.0) 15.6 (27.2) 6.1 (37.1) 26.0 (24.0) 18.7 (26.7) 7.3 (36.9)
Dynamic mechanical allodynia? 0.50
Yes (n 5 3) 7.8 (13.5) 23.4 (9.6) 11.2 (10.0) 0.95 21.9 (10.6) 19.3 (21.4) 2.7 (28.2)
No (n 5 21) 24.6 (23.9) 12.7 (29.1) 11.9 (40.5) 30.3 (25.0) 13.3 (29.5) 17.0 (40.4)
Cold allodynia?
Yes (n 5 4) 28.0 (29.3) 17.5 (21.8) 10.5 (41.5) 0.95 40.1 (22.8) 20.2 (31.2) 19.9 (51.2) 0.84
No (n 5 20) 21.4 (22.8) 9.3 (29.2) 12.1 (38.3) 27.0 (23.8) 12.8 (28.4) 14.2 (37.5)
Warmth allodynia?
Yes (n 5 1) 0 (N/A) 0 (N/A) 0 (N/A) N/A 33.3 (N/A) 0 (N/A) 33.3 (N/A) N/A
No (n 5 23) 23.5 (23.4) 11.2 (28.4) 12.3 (38.7) 29.0 (24.2) 14.6 (28.8) 14.4 (39.5)
Pain reduction is shown as average (SD). P values shown for 2-tailed, unpaired t-tests for difference in pain reduction for pregabalin vs placebo.
Table 6
Baseline hyperesthesia and allodynia to static mechanical, dynamic mechanical, cold, and warm stimulation as predictors of
‡30% decrease in average daily pain.
Sensory finding Pregabalin Placebo
‡30% analgesia <30% analgesia P ‡30% analgesia <30% analgesia P
Static mechanical hyperesthesia
Present 6 6 0.695 2 9 0.661
Absent 5 8 4 10
Static mechanical allodynia
Present 2 3 1.000 0 5 0.289
Absent 9 11 6 14
Dynamic mechanical hyperesthesia
Present 3 6 0.677 3 7 0.653
Absent 8 8 3 12
Dynamic mechanical allodynia
Present 0 3 0.230 0 3 0.554
Absent 11 11 6 16
Cold hyperesthesia
Present 8 4 0.047 3 10 1.000
Absent 3 10 3 9
Cold allodynia
Present 2 2 1.000 1 3 1.000
Absent 9 12 5 16
Warmth hyperesthesia
Present 2 0 0.183 0 2 1.000
Absent 9 14 6 17
Warmth allodynia
Present 0 1 1.000 0 1 1.000
Absent 11 13 6 18
Absolute number of participants displaying hyperesthesia or allodynia to cold, warmth, brush, and pinprick stimulation as a predictor of decrease in average daily pain. Static mechanical hyperesthesia/allodynia was assessed
using Semmes-Weinstein 6.10 monofilament. All P values are for the Fisher exact test.
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spontaneous improvement in their pain during the study, as
painful CIPN improves in some patients in the first 12months after
onset. Finally, we cannot extrapolate these results to patients with
CIPN from chemotherapy agents beyond those included in this
study, such as vinca alkaloids, bortezomib, and others.16
Skin biopsy results showed no correlation between IENFD and
changes in average or worst pain with pregabalin. Notably, no
participants who consented to biopsy had spontaneous pain
extending proximally to the biopsy site (10 cm proximal to the
lateral malleolus). This site was chosen based on the guidelines of
the European Federation of Neurological Societies (EFNS).26
Recent evidence suggests that the correlation between biopsy
and functional measures in length-dependent neuropathies may
vary depending on the site24; therefore, results may have differed
in patients with spontaneous pain extending proximally to the
ankle.
The study has notable strengths. It is one of the first studies
aimed primarily at assessing phenotypic predictors of response
to treatment in CIPN. We applied rigorous inclusion criteria and
performed detailed somatosensory phenotyping both with
comprehensive and bedside QST approaches. We used
electronic diaries for documentation of pain and adverse effects
aswell as for adherence improvement andmonitoring. Given data
on the superiority of electronic data capture methods (including
improved protocol compliance, lower rates of data falsification,
and fewer data entry errors8), this method is likely to result in more
reliable patient-reported outcomes. Finally, our pregabalin
plasma concentration assays suggest that participants reliably
adhered to their allocated treatment arms. No participants in the
placebo arm demonstrated detectable pregabalin levels, and
91% of participants in the pregabalin arm demonstrated detect-
able pregabalin levels. Two subjects in the pregabalin arm had
concentrations below LOQ. It is possible that these subjects did
not adhere to study protocol; however, both took the lowest
presampling pregabalin dose at the end of drug taper off, and the
period between last pregabalin dose and sample collection for
both was more than 2 SDs longer than the average period for the
remaining subjects.
In conclusion, MPT does not meaningfully predict response to
pregabalin for painful CIPN. Over a 4-week treatment period,
average or worst spontaneous pain reduction in CIPN was not
significantly larger with pregabalin compared to placebo. Several
neuropathic pain–specific measures on NPSI questionnaire
demonstrated better improvement with pregabalin than with
placebo. Dizziness and somnolence were significantly more
frequent in the pregabalin group. Additional research is needed to
identify critically important phenotypic and outcome measure
parallels between animal pain models and clinical conditions to
improve the translatability of pain research for achieving better,
personalized treatment of neuropathic pain.
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